KRC-00715

KRC-00715 is an effective oral c-Met inhibitor with an IC50 of 9.0 nM, demonstrating high selectivity in gastric cancer cells. KRC-00715 specifically inhibits the growth of c-Met-highly expressed cell lines by inducing G1/S phase arrest, leading to a reduction in downstream signaling pathways, including Akt and Erk, as well as c-Met activity. KRC-00715, in the gastric cancer cell line Hs746, is characterized by an IC50 of 39 nM, and it selectively inhibits the proliferation of c-Met-highly expressed cell lines. KRC-00715 reduces tumor size in Hs746T xenograft mouse models.


Cat. No.: EX-A12797	Purity: >98%

	Chemical structure of KRC-00715

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order
1g	get quote	Inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2079853-72-6
Purity	>98%
Formula	C25H25F3N8O3
Mol Weight	542.513
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Chi Hoon Park, et al. Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.BMC Cancer. 2016 Jan 22:16:35.
CoA	CoA of KRC-00715

Smiles:	FC(F)(F)C1=C(OCCN2CCOCC2)C=CC(C3=NC(N(CC4OC(C=CC=N5)=C5NC4)N=N6)=C6N=C3)=C1


		Search